Tech Company Financing Transactions
Triumvira Immunologics Funding Round
B Capital Group, ATEM Capital and Leaps by Bayer participated in a $100 million Series A funding round for Triumvira Immunologics. The financing round was announced on 3/17/2022.
Transaction Overview
Company Name
Announced On
3/17/2022
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Crystal Mountain At Barton Creek
Austin, TX 78733
USA
Austin, TX 78733
USA
Phone
Website
Email Address
Overview
Triumvira Immunologics, Inc. (Triumvira) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Lammers
Chief Medical Officer
Sabine Chlosta
Chief Scientific Officer
Jonathan Bramson
Chief Technical Officer
Donna Rill
VP - Bus. Development
Joshua Carle
VP - Finance
Jon Irvin
VP - R & D
Andreas Bader
VP - Regulatory Affairs
Cynthia Molina
Browse more venture capital transactions:
Prev: 3/17/2022: Getir venture capital transaction
Next: 3/17/2022: HUBUC venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to record all VC transactions involving tech companies. VC investment data records on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs